Inventor · disambiguated record
Wenbin Ying
Also filed as: YING WENBIN
54 granted patents·15 pending applications·360 citations·filing 2002–2025
98Inventor score
Top patents by PatentIndex Score
69 records- 0195US9771582B2RNA interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2015·Granted Sep 26, 2017·13 cites·35 claims
- 0295US8741867B2Retinoid-liposomes for treating fibrosisNIITSU YOSHIRO·Filed 2012·Granted Jun 3, 2014·34 cites·29 claims
- 0395US8664376B2Retinoid-liposomes for enhancing modulation of HSP47 expressionNIITSU YOSHIRO·Filed 2012·Granted Mar 4, 2014·30 cites·26 claims
- 0495US7084141B2Inhibitors of macrophase migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2005·Granted Aug 1, 2006·27 cites·44 claims
- 0594US7361760B2Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseasesAVANIR PHARMACEUTICALS·Filed 2007·Granted Apr 22, 2008·31 cites·19 claims
- 0694US7173036B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2004·Granted Feb 6, 2007·45 cites·45 claims
- 0793US10196637B2Retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·7 cites·20 claims
- 0893US10047111B2RNA interference agents for GST-PI gene modulationNITTO DENKO CORP·Filed 2015·Granted Aug 14, 2018·11 cites·23 claims
- 0992USRE48887ERNA interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2019·Granted Jan 11, 2022·2 cites·35 claims
- 1092US10047110B2RNA agents for GST-Pi gene modulationNITTO DENKO CORP·Filed 2015·Granted Aug 14, 2018·8 cites·10 claims
- 1192US10023597B2RNA interference agents for p21 gene modulationNITTO DENKO CORP·Filed 2017·Granted Jul 17, 2018·6 cites·9 claims
- 1292US9580710B2Methods and compositions for treating malignant tumors associated with KRAS mutationNITTO DENKO CORP·Filed 2015·Granted Feb 28, 2017·7 cites·27 claims
- 1391US11926831B2SiRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2022·Granted Mar 12, 2024·1 cites·18 claims
- 1491US9695206B2RNA interference agents for P21 gene modulationNITTO DENKO CORP·Filed 2015·Granted Jul 4, 2017·6 cites·8 claims
- 1591US7312221B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Dec 25, 2007·12 cites·17 claims
- 1690US10300018B2Compositions and methods for nanoparticle lyophile formsNITTO DENKO CORP·Filed 2016·Granted May 28, 2019·4 cites·29 claims
- 1790US7514225B2Method for screening an agent that modulates activity of macrophage migration inhibitory factorAVANIR PHARMACEUTICALS·Filed 2005·Granted Apr 7, 2009·8 cites·11 claims
- 1889US11390871B2SiRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2019·Granted Jul 19, 2022·3 cites·22 claims
- 1989US9456984B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2014·Granted Oct 4, 2016·10 cites·58 claims
- 2089US7105519B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2002·Granted Sep 12, 2006·17 cites·107 claims
- 2188US10167253B2Ionizable compounds and compositions and uses thereofNITTO DENKO CORP·Filed 2016·Granted Jan 1, 2019·6 cites·16 claims
- 2288US7235546B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Jun 26, 2007·7 cites·24 claims
- 2387US11737982B2Compositions and methods for nanoparticle lyophile formsNITTO DENKO CORP·Filed 2019·Granted Aug 29, 2023·2 cites·4 claims
- 2487US10358647B2siRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2016·Granted Jul 23, 2019·6 cites·21 claims
- 2587US9308267B2Lipids for therapeutic agent delivery formulationsNITTO DENKO CORP·Filed 2013·Granted Apr 12, 2016·8 cites·21 claims
- 2687US7129236B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Oct 31, 2006·5 cites·42 claims
- 2786US11384051B2Ionizable compounds and compositions and uses thereofNITTO DENKO CORP·Filed 2018·Granted Jul 12, 2022·2 cites·14 claims
- 2886US10792299B2Methods and compositions for treating malignant tumors associated with kras mutationNITTO DENKO CORP·Filed 2017·Granted Oct 6, 2020·3 cites·19 claims
- 2986US7365200B2Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitorsAVANIR PHARMACEUTICALS·Filed 2007·Granted Apr 29, 2008·9 cites·22 claims
- 3086US7312220B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Dec 25, 2007·6 cites·31 claims
- 3185US10195145B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·4 cites·31 claims
- 3285US2024425862A1Sirna structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2024·Application pending·0 cites
- 3384US7732146B2Method for screening an agent that modulates activity of macrophage migration inhibitory factorAVANIR PHARMACEUTICALS·Filed 2005·Granted Jun 8, 2010·3 cites·9 claims
- 3484US7192961B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Mar 20, 2007·3 cites·27 claims
- 3582US12311055B2Compositions and methods for nanoparticle lyophile formsNITTO DENKO CORP·Filed 2023·Granted May 27, 2025·0 cites·19 claims
- 3682US11413243B2Fusogenic compounds for delivery of biologically active moleculesNITTO DENKO CORP·Filed 2018·Granted Aug 16, 2022·1 cites·23 claims
- 3782US10441659B2Lipids for therapeutic agent delivery formulationsNITTO DENKO CORP·Filed 2015·Granted Oct 15, 2019·3 cites·22 claims
- 3882US7432374B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2007·Granted Oct 7, 2008·2 cites·7 claims
- 3981US7435737B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Oct 14, 2008·2 cites·11 claims
- 4080US2022087531A1Rna interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2021·Application pending·0 cites
- 4179US12319643B2Ionizable compounds and compositions and uses thereofNITTO DENKO CORP·Filed 2022·Granted Jun 3, 2025·0 cites·12 claims
- 4278US7238809B2Process for the preparation of inhibitors of macrophage migration inhibitory factorAVANIR PHARMACEUTICALS·Filed 2006·Granted Jul 3, 2007·1 cites·24 claims
- 4378US7235565B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Jun 26, 2007·1 cites·52 claims
- 4478US7230106B2Process for the preparation of inhibitors of macrophage migration inhibitory factorAVANIR PHARMACEUTICALS·Filed 2006·Granted Jun 12, 2007·1 cites·19 claims
- 4578US7202248B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Apr 10, 2007·1 cites·62 claims
- 4678US7157469B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Jan 2, 2007·1 cites·42 claims
- 4777US2025250226A1Ionizable compounds and compositions and uses thereofNITTO DENKO CORP·Filed 2025·Application pending·0 cites
- 4876US12440445B2Fusogenic compounds for delivery of biologically active moleculesNITTO DENKO CORP·Filed 2022·Granted Oct 14, 2025·0 cites·11 claims
- 4976USRE49431ERNA interference agents for GST-PI gene modulationNITTO DENKO CORP·Filed 2020·Granted Feb 28, 2023·0 cites·23 claims
- 5076US7192955B2Inhibitors of macrophage migration inhibitory factor and methods for identifying the sameAVANIR PHARMACEUTICALS·Filed 2006·Granted Mar 20, 2007·1 cites·52 claims
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Wenbin Ying files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →